NCT07321899ClinicalTrials.gov
Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation
Transcatheter Tricuspid Valve Replacement Using the Medtronic Intrepid™ TTVR System in Patients With Severe Symptomatic Tricuspid Regurgitation - PATHFINDER
In brief
This clinical trial evaluates the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in symptomatic patients with severe or greater tricuspid regurgitation.
Interventional1,186 participants sought20 sites1 country
Categories
Registered in 1 registry
- ClinicalTrials.govNCT07321899Open this record at ClinicalTrials.govSynced last week
One study can be registered in several registries. We show it once and link every record we hold.
Trial information is shown as published by the registry, in its original language.
Interested in this study?
Sign in or create an account to register your interest and follow this study.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-01-07; recorded start 2026-09-11
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 19 other studies in this databaseCounted from the lead sponsor named in the record (Medtronic Cardiovascular)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a study of this type, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding7/20
Single-blind
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre5/8
Multi-centre: 4 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study: 1,186 participants (target), run at 20 sites.
How this score is built
- Enrolment31/40
1,186 participants (target)
- Site count7/25
4 sites
- Country count0/15
Single country
- Planned duration10/10
Planned over about 179 months
- Sponsor scale4/10
Medtronic Cardiovascular has led 19 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Summary
This clinical trial evaluates the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in symptomatic patients with severe or greater tricuspid regurgitation.
Conditions
- Severe Tricuspid Regurgitation
Eligibility
| Sex | All |
|---|---|
| Ages | 18 Years – No maximum |
| Healthy volunteers | No |
Eligibility as written in the registry
Eligibility in plain statements
This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.
Study design
| Study type | Interventional |
|---|---|
| Phase | Not applicable |
| Allocation | Randomised |
| Intervention model | PARALLEL |
| Primary purpose | TREATMENT |
| Masking | SINGLE (1) |
| Enrolment | 1,186 participants sought |
Sponsor and collaborators
- Medtronic Cardiovascular Sponsor
Arms and interventions
- Medtronic Intrepid™ TTVREXPERIMENTAL
Transcatheter tricuspid valve replacement with Medtronic Intrepid™ TTVR System in patients with severe or greater tricuspid regurgitation.
- Edwards EVOQUE TTVRACTIVE_COMPARATOR
Transcatheter tricuspid valve replacement with Edwards EVOQUE TTVR in patients with severe or greater tricuspid regurgitation.
- Single Arm RegistryEXPERIMENTAL
Transcatheter tricuspid valve replacement with Medtronic Intrepid™ TTVR System in patients with severe or greater tricuspid regurgitation who are not eligible for randomization.
Interventions
- Device Edwards EVOQUE Tricuspid Valve Replacement (TTVR) System
Transcatheter Tricuspid Valve Replacement
- Device Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System
Transcatheter Tricuspid Valve Replacement
Outcome measures
Primary outcome
Rate of Major Adverse Events (MAE)
Time frame 30-days post-procedure
Primary outcome
Composite Endpoint: All-cause mortality, Heart failure hospitalization, and tricuspid valve reintervention
Time frame 1-year post-procedure
Secondary outcome
Tricuspid regurgitation (TR) grade reduction
Total number of patients with at least one grade TR reduction
Time frame 6 months post-procedure
Secondary outcome
Change in quality of life (QoL) as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline
KCCQ overall summary score is a patient-reported measure of health status. Scores range from 0 to 100 where higher scores reflect better quality of life
Time frame 6 months post-procedure
Secondary outcome
All-cause mortality
Time frame 12 months post-procedure
Secondary outcome
Heart failure hospitalization
Time frame 12 months post-procedure
Secondary outcome
New onset conduction disturbance (NOCD)
Time frame 30 days post-procedure
Secondary outcome
Total procedure time
Time frame Procedure
Secondary outcome
Right ventricle (RV) dysfunction
Time frame 12 months post-procedure
Dates
| Start date | September 11, 2026 (actual) |
|---|---|
| Primary completion | September 1, 2031 (estimated) |
| Completion | April 1, 2041 (estimated) |
| First posted | January 7, 2026 (actual) |
| Last updated | November 12, 2026 |
| Results posted | Not stated in the registry record |
| Status last verified | November 2026 |
Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.
Locations
20 sites are recruiting
United States
| Facility | City | State or region | Status |
|---|---|---|---|
| Emory University Hospital Midtown | Atlanta | Georgia | Recruiting |
| University of Alabama at Birmingham (UAB) Hospital | Birmingham | Alabama | Recruiting |
| Buffalo General Medical Center | Buffalo | New York | Recruiting |
| Northwestern Memorial Hospital | Chicago | Illinois | Recruiting |
| The Christ Hospital | Cincinnati | Ohio | Recruiting |
| Cleveland Clinic Foundation | Cleveland | Ohio | Recruiting |
| Hartford Hospital | Hartford | Connecticut | Recruiting |
| Cedars Sinai Medical Center | Los Angeles | California | Recruiting |
| Northwell Health North Shore University Hospital | Manhasset | New York | Recruiting |
| Abbott Northwestern Hospital | Minneapolis | Minnesota | Recruiting |
| Morristown Medical Center | Morristown | New Jersey | Recruiting |
| Yale New Haven Hospital | New Haven | Connecticut | Recruiting |
| Montefiore Medical Center | New York | New York | Recruiting |
| NYU Langone Medical Center | New York | New York | Recruiting |
| The Valley Hospital | Paramus | New Jersey | Recruiting |
| Abrazo Arizona Heart Hospital | Phoenix | Arizona | Recruiting |
| Kaiser Permanente San Francisco Medical Center | San Francisco | California | Recruiting |
| Los Robles Hospital & Medical Center | Thousand Oaks | California | Recruiting |
| Ascension Via Christi Saint Francis | Wichita | Kansas | Recruiting |
| Lankenau Institute for Medical Research | Wynnewood | Pennsylvania | Recruiting |
Study documents
No documents are linked in this registry record.
Changes over time
- November 12, 2026
Site added
7 sites added (20 total)
1320
- September 25, 2026
Site added
9 sites added (13 total)
413
- July 28, 2026
Status changed
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- July 28, 2026
Recruitment opened
Recruitment opened
NOT_YET_RECRUITINGRECRUITING
- July 28, 2026
Site added
4 sites added (4 total)
04